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Summary
Meta-analysis of individual participant data (IPD) is considered the "gold-standard"
for synthesizing clinical study evidence. However, gaining access to IPD can be a
laborious task (if possible at all) and in practice only summary (aggregate) data are
commonly available. In this work we focus on meta-analytic approaches of compar-
ative studies where aggregate data are available for continuous outcomes measured
at baseline (pre-treatment) and follow-up (post-treatment). We propose a method
for constructing pseudo individual baselines and outcomes based on the aggregate
data. These pseudo IPD can be subsequently analysed using standard analysis of
covariance (ANCOVA) methods.
Pseudo IPD for continuous outcomes reported at two timepoints can be generated
using the sufficient statistics of an ANCOVA model i.e., the mean and standard
deviation at baseline and follow-up per group, together with the correlation of the
baseline and follow-up measurements. Applying the ANCOVA approach, which
crucially adjusts for baseline imbalances and accounts for the correlation between
baseline and change scores, to the pseudo IPD results in identical estimates to the
ones obtained by an ANCOVA on the true IPD. In addition, an interaction term
between baseline and treatment effect can be added. There are several modelling
options available under this approach, which makes it very flexible.
Methods are exemplified using reported data of a previously published IPD meta-
analysis of 10 trials investigating the effect of antihypertensive treatments on systolic
blood pressure, leading to identical results compared with the true IPD analysis and
of a meta-analysis of fewer trials, where baseline imbalance occurred.
KEYWORDS:
meta-analysis, pseudo individual participant data, ANCOVA, sufficient statistics
7
21 INTRODUCTION8
Meta-analysis methods of individual participant data or individual patient data (IPD) are considered the "gold-standard" for9
clinical studies’ evidence synthesis1,2,3,4. IPD meta-analysis has several advantages over the traditional aggregate data (AD)10
meta-analysis approach, which synthesizes summary statistics per study, often retrieved from published sources. For example11
when continuous outcomes are available at baseline and follow-up, IPD meta-analysis enables the meta-analyst to perform12
adjustments for baseline imbalances and detailed explorations of treatment-covariate interactions5,6,7. In addition, it comes with13
a large toolbox of methods and greater flexibility to analyse the data in an one-stage or two-stage approach8,9,10,11.14
There are, however, challenges as access to IPD can be problematic because of time and cost constraints and privacy issues,15
and often it is not feasible to retrieve the IPD of all studies to be synthesized. It is possible to generate/back-calculate IPD16
for different types of AD, such as for binary, ordinal and time to event outcomes12,13,14,15. For aggregate data of continuous17
outcomes reconstructing the original outcome values is not possible. However, we recently proposed an algorithm to construct18
pseudo IPD for an one-stage meta-analysis with one continuous outcome, using the sufficient statistics for linear mixed models19
i.e., group means, standard deviations and sample sizes16. In this way the analysis using the pseudo IPD yields exactly the same20
results as the analysis of the original IPD. The pseudo IPD approach allowed more flexible modeling, using standard linear21
mixed model software, for example enabling common or different residual variances for treatment and control groups in each22
study.23
In this paper we extend the original method of creating pseudo IPD from reported AD to the situation where continuous out-24
comes are reported both at baseline and follow-up. We discuss how pseudo IPD can be derived, taking the correlation between25
baseline and follow-up/final measurements into account, using the summary observed group means, standard deviations at26
baseline and post-treatment, and the group correlation of the baseline and post-treatment values (or equivalently the standard27
deviations of the difference between baseline and post-baseline values in both groups). These summary measures are the suf-28
ficient statistics for an analysis of covariance (ANCOVA) approach under the linear mixed model (LMM) framework. The29
generated pseudo IPD can be analysed using standard software for linear mixed models, and a linear mixed model analysis of30
the pseudo IPD will yield identical results to the ones obtained when it is applied on the original IPD.31
We describe the advantages of this approach, compared with the standard methods to synthesize aggregate baseline and32
follow-up data: using mean follow-up (post-treatment/final) scores, ignoring the baseline values and mean change scores,33
subtracting the follow-up value from the baseline17,18.34
It is possible to perform a meta-analysis in an one-stage or a two-stage approach using the pseudo IPD, using the toolbox of35
available IPD methods8,9,10,11. A plethora of modelling options is available and we discuss several options, assuming stratified36
and random study intercepts and random treatment effect models.37
The flexibility of the linear mixed modelling framework makes it possible to correct for potential baseline imbalances.38
Although imbalance at baseline is not expected in a randomised trial, it can occur by chance, particularly in small trials19 or39
due to flaws in the randomisation process20.40
Treatment effects may also differ between patients, depending on their baseline values. For example, in a trial for hyperten-41
sion, patients with low systolic blood pressure at baseline are expected to experience less improvement after administration of42
treatment, compared with patients having high baseline pressure values. Similarly, severely depressed patients with high val-43
ues on a depression score may profit more from treatment than patients with mild depression. When generating and analysing44
pseudo IPD using an ANCOVA approach we can cope with the correlation between the baseline value and the change score by45
introducing an interaction term between the baseline measurement and the treatment effect. In this way treatment heterogeneity46
depending on the baseline values can be further explored.47
The paper is organized as follows. In Section 2 we introduce two illustrating meta-analysis datasets: one in hypertension48
where group-level AD of systolic blood pressure (SBP) at baseline and at follow-up for anti-hypertensive treatments versus49
placebo/no treatment are available from a previous IPD meta-analysis publication21 and a second example where active versus50
sham treatments in obstructive sleep apnea are compared and baseline imbalance occured between the treatment groups22.51
In Sections 3 and 4, we describe some of the existing modelling options for one-stage and two-stage IPD meta-analyses,52
respectively, including models for treatment-by-baseline interaction. In Section 5, we explain how pseudo IPD baselines and53
outcomes can be generated from the aggregate continuous data in the case of correlated baseline and final measurements. In54
Section 6, we apply our proposed method to the hypertension dataset in/excluding an investigation of the interaction between55
0Abbreviations: AD, aggregate data; CI: confidence interval, IPD, individual patient (participant) data; RCT, randomised controlled trial
3baseline and treatment and compare the results with those obtained when using the original IPD as previously reported in the56
work of Riley et al.21,23 and with standard two-stage methods on the AD. In addition, we apply the pseudo IPD approach on the57
sleep apnea dataset and compare the results of the pseudo IPD ANCOVA models, while varying group-correlations coefficients58
(as sensitivity analysis), with change scores AD meta-analysis. Brief final comments are provided in Section 7.59
2 ILLUSTRATING EXAMPLES60
2.1 Aggregate data from 10 trial in hypertension with baseline imbalance and artificial baseline61
imbalance62
We use the reported aggregate data for studies originally contained in an IPD meta-analysis of Wang et al.24, and subsequently63
analysed by Riley et al.21 investigating the effect of hypertension treatments on systolic blood pressure (SBP). The authors64
included IPD of trials comparing antihypertensive treatments against placebo/no treatment25 26,27,28. A total of 28 851 patients65
from 10 trials were included. Each trial measured blood pressure at baseline and after treatment. The aggregate data for each66
trial, including the mean, standard deviation and correlation of the baseline and the final SBP values (in mmHg) are shown in67
Table 1. Riley et al.21 compared several meta-analytic approaches to estimate the summary treatment effect of antihypertension68
treatments in reducing SBP using the original IPD and compared them to standard AD methods. In this article, we re-analyse69
these data using only the aggregate group means, standard deviations and correlations of the baseline and the final values and70
apply our algorithm to generate pseudo IPD. We also perform standard AD meta-analysis using change scores and provide a71
comparison of the different methods. Riley et al.21 explored the effect of large baseline imbalance by modifying the original72
hypertension dataset. This was achieved by subtracting 5 mmHg from the baseline and final SBP values of patients in the73
treatment group of trials 1 and 2; 20 mmHg of patients in the treatment group of trials 4 and 5 and 10 mmHg of the baseline74
and final values of patients in the treatment group of trial 6 accordingly, such that five studies have lower baseline values in the75
treatment group compared with the control group. We also demonstrate our method on the aggregate version of this modified76
dataset.77
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TABLE 1 Aggregate data of the 10 hypertension trials included in the meta-analysis of Wang et al.24 as reported by Riley et al.21
Number of subjects SBP baseline (mmHg) SBP final (mmHg) Correlation (SBP baseline, SPB final)
Treatment Control Treatment Control
ID Trial name Treatment Control Mean (SD) Mean (SD) Mean (SD) Mean (SD) Treatment Control
1 ATMH 780 750
152.28
(15.25)
153.05
(15.73)
132.85
(16.72)
139.75
(17.85)
0.265 0.284
2 HEP 150 199
189.94
(16.15)
191.55
(17.64)
165.06
(20.03)
179.89
(22.15)
0.335 0.331
3 EWPHE 90 82
177.33
(15.85)
178.23
(15.06)
156.88
(21.26)
170.45
(26.91)
0.462 0.534
4 HDFP 2427 2370
151.68
(19.83)
151.00
(19.53)
130.09
(19.25)
138.54
(21.26)
0.337 0.408
5 MRC-1 3546 3445
156.60
(16.09)
156.65
(15.96)
135.49
(16.32)
144.25
(17.58)
0.346 0.416
6 MRC-2 1314 1337
182.19
(12.63)
182.13
(12.73)
153.99
(20.13)
164.58
(19.71)
0.178 0.137
7 SHEP 2365 2371
170.49
(9.5)
170.12
(9.24)
145.10
(19.05)
156.24
(20.12)
0.315 0.253
8 STOP 137 131
194.68
(12.21)
194.15
(11.16)
171.46
(19.29)
189.11
(21.9)
0.177 0.414
9 Sy-Chi 1252 1139
170.73
(10.9)
170.25
(11.41)
150.2
(15.84)
156.55
(16.86)
0.199 0.347
10 Sy-Eur 2398 2297
173.75
(9.86)
173.94
(10.07)
154.87
(16.31)
165.24
(16.33)
0.319 0.431
ATMH: Australian Trial in Mild Hypertension, HDFP: Hypertension Detection and Follow-up Programme, EWPHE: European Working Party on High Blood Pressure in the Elderly, MRC: Medical Research Council, SBP: systolic blood pressure, SD: standard deviation, SHEP: Systolic Hypertension in the Elderly
Programme, STOP: Swedish Trial in Old Patients with Hypertension, Sy-Chi: Systolic Hypertension in China, Sy-Eur: Systolic Hypertension in Europe
52.2 Aggregate data from 8 trials in obstructive sleep apnea with baseline imbalance78
Aggregate data from a review of treatments for obstructive sleep apnea in adults22 were used. We focus on a meta-analysis79
summarising the treatment effect of an active continuous positive airway pressure (CPAP) device versus a sham CPAP. Eight80
studies, of in total 311 patients, recorded the apnea-hypopnea index (AHI), which is defined as the number of apnea and81
hypoapnea events divided by the total hours of sleep, at baseline and follow-up. The authors22 estimated a statistically significant82
mean difference in change scores of AHI between active CPAP and sham, favoring CPAP (difference -46 events/hour 95% CI:83
[-57, -36]; blue/triangle, Figure 1). We re-analysed these data, taking into account the considerable baseline imbalance which84
occured between the treatment groups (difference of 5 events/hour, 95% CI [0, 11]– the subjects randomised in the active CPAP85
arm suffered more severely from sleep apnea; red/circle, Figure 1), and explored whether patients with higher AHI at baseline86
benefitted more from treatment. For comparison purposes, we have additionally included the summary estimates of the final87
values analysis, which is not preferred due to baseline imbalance (green/square, Figure 1).88
FIGURE 1 Obstructive sleep apnea meta-analysis example: forest plot of three different summary measures : a) difference in
final values between mean AHI in the active CPAP group and mean AHI in the sham CPAP group (green/square); b) between
groups difference in mean change from baseline (blue/triangle); c) between groups difference in mean AHI score at baseline
(red/circle). The lowest line gives the results from a standard random effects meta-analysis.
3 ONE-STAGE IPD META-ANALYSIS USING LINEAR MIXED MODELS (LMM)89
In this section, we introduce notation and modelling options, for an one-stage meta-analysis of IPD of studies measuring90
continuous outcomes ast baseline and follow-up. The data we consider have the following format: let 푌퐵푖푗 denote the continuous91
outcome of interest ( i.e., SBP) at baseline/pre-treatment of patient 푗 in study 푖(1, ..., 푁) and 푌퐹 푖푗 the outcome, of each patient92
post-treatment (at follow-up). Also, let 푋푖푗 be a dummy variable to indicate the treatment group; 푋푖푗=1 for patients in the93
treatment group and 0 for patients in the control group, respectively. There are many IPD meta-analysis ANCOVA type model94
options. A number of them are presented in this section; a similar description of the ANCOVA model can be found in Burke et95
al.896
63.1 Analysis of covariance (ANCOVA)97
3.1.1 Stratified study model98
An analysis of covariance (ANCOVA) model, with study-specific stratified intercepts and stratified adjustment terms for
baseline measurements may be written as follows:
푌퐹 푖푗 = 훽0푖 + (훽1 + 푏1푖)푋푖푗 + 훽2푖(푌퐵푖푗 − 푌̄퐵푖) + 휖푖푗 , (1)
where 훽0푖 is the mean outcome in the control group in study 푖 for individuals with the mean baseline value, 훽1 the summary99
(average) treatment effect and 훽2푖 is the study-specific adjustment term for baseline values. A random effect 푏1푖 is added to100
the overall treatment effect, which is assumed to be normally distributed with mean 0 and between-study variance equal to101
휏21 . Although a random treatment effect is preferred, one can assume a common (fixed) treatment effect by constraining 휏
2
1=0.102
There are several modelling options for the variance of the within-study residuals, 휖푖푗 , on which we elaborate later on.103
3.1.2 Random study model104
An alternative approach to using stratified study intercepts and slopes is to assume a random intercept and a random baseline
adjustment effect, resulting in the following ANCOVA model:
푌퐹 푖푗 = (훽0 + 푏0푖) + (훽1 + 푏1푖)푋푖푗 + (훽2 + 푏2푖)(푌퐵푖푗 − 푌̄퐵푖) + 휖푖푗 , (2)
푤ℎ푒푟푒
⎡⎢⎢⎣
푏0푖
푏1푖
푏2푖
⎤⎥⎥⎦ ∼푀푉푁
⎛⎜⎜⎝
⎡⎢⎢⎣
0
0
0
⎤⎥⎥⎦ ,
⎡⎢⎢⎣
휏20 휏01 휏02
휏01 휏21 휏12
휏02 휏12 휏22
⎤⎥⎥⎦
⎞⎟⎟⎠
Parameters are as in Equation (1), except for a random intercept and baseline adjustment coefficient; with 휏21 denoting the105
between-study variance of the treatment effect. In the literature, is it often assumed that the random effects are independent (i.e,106
휏푖푗 = 0 for 푖 ≠ 푗), although under the LMM it is possible to estimate their covariances.107
3.2 Analysis of covariance (ANCOVA) including treatment-by-baseline interaction108
To investigate potential treatment effect modification by the baseline value, the equations (1) and (2) can be extended by109
including the interaction term between baseline and treatment effect. The stratified study model (1) incorporating the ”treatment-110
covariate interaction” is as follows:111
푌퐹 푖푗 = 훽0푖 + (훽1 + 푏1푖)푋푖푗 + 훽2푖(푌퐵푖푗 − 푌̄퐵푖) + (훽3 + 푏3푖)[(푌퐵푖푗 − 푌̄퐵푖)푋푖푗] + 훽4푖(푌̄퐵푖푋푖푗) + 휖푖푗 (3)
While the other parameters are as in Equation (1), 훽3 denotes the mean increase in treatment effect for a one-unit increase112
in the baseline values and the random effect 푏3푖 allows for between studies heterogeneity in the treatment-covariate interaction.113
This estimate reflects the within-trial interaction effect and 훽4푖 estimates the increase in the treatment effect associated with a114
one-unit increase between the mean baseline of two studies, which reflects the across-trial interaction. Centering the baseline115
values and appropriately separating within- and across trial-associations avoids ecological bias, a phenomenon where the asso-116
ciations are erroneously equated29. Note that if the 훽4푖(푌̄퐵푖푋푖푗) is omitted from model (4), then the interaction term will reflect117
a weighed average of 훽3 and the magnitude of the ecological bias30.118
Similarly, equation (2) can be extended yielding a random study ANCOVA model allowing for the interaction between119
baseline and treatment, which is formulated as follows:120
푌퐹 푖푗 = (훽0 + 푏0푖) + (훽1 + 푏1푖)푋푖푗 + (훽2 + 푏2푖)(푌퐵푖푗 − 푌̄퐵푖) + (훽3 + 푏3푖)[(푌퐵푖푗 − 푌̄퐵푖)푋푖푗] + 훽4푖(푌̄퐵푖푋푖푗) + 휖푖푗 (4)
This model has four random effects (푏0푖, 푏1푖, 푏2푖, 푏3푖), the covariance matrix of which may either be completely unspecified121
or may be modelled, for example by assuming independence of the different random effects.122
Although, many other modelling specifications are possible, in this work we consider models (1) to (4).123
73.3 Within-study residual variances124
The within-study residuals 휖푖푗 are assumed to follow a normal distribution with mean 0. The within-study residual variance 휎2푖푘125
may depend on the study 푖 and group 푘. We explore four structures for modelling 휎2푖푘: all variances assumed different (arm- and126
study-specific): 휖푖푘 ∼ 푁(0, 휎2푖푘), study-specific variances: 휎
2
푖푘 = 휎
2
푖., one variance for control and one variance for treated group127
휎2푖푘 = 휎
2
.푘, which are the same for all studies and one overall variance: 휎
2
푖푘 = 휎
2.128
4 TWO-STAGE IPD META-ANALYSIS APPROACH129
Instead of modelling all IPD in one model, in practice it may be more convenient to use a two-step approach. In the first stage,
a separate ANCOVA is fitted in each of the studies 푖 = 1 to 푁 .
푌퐹 푖푗 = 훽0푖 + 훽1푖푋푖푗 + 훽2푖푌퐵푖푗 + 휖푖푗 (5)
This yields 푁 treatment effects 훽̂1푖 with standard errors 푠푒푖.130
At the second stage a common (fixed)-effect or random-effects meta-analysis is run on the estimated study-specific 훽1푖푠.131
In principle, the one-stage and two-stage approaches produce very similar results yet minor differences may arise as the132
former estimates the within-study residual variances simultaneously with 훽1푖 and 휏21 while under the two-stage approach the133
within-study residual variances are estimated separately as seen in Eq (5) and independently of 훽1푖 and 휏21 in the second stage. In134
particular, the stratified study one-stage model (1) and two-stage IPD meta-analysis approaches will yield very similar results,135
under the same underlying (modelling) assumptions, for example equal variance for treatment and control within studies8.136
For small sample sizes the results may deviate slightly. Equation (5) can also be extended to estimate the interaction between137
baseline values and treatement effect by introducing the interaction term similar to term 훽3 from Eq (3).138
5 CONSTRUCTION OF PSEUDO IPD FROM AGGREGATE DATA139
In our previous work we developed a method to generate pseudo IPD for a single continuous outcome per subject without140
baseline values16. The method generates data with the same observed means, standard deviations and sample sizes, the so-141
called pseudo IPD. Because the means and standard deviations are the sufficient statistics, the likelihood function for the IPD,142
using the linear mixed model is identical to the likelihood of the unknown true IPD. This means that analysing the pseudo IPD143
with LMM will yield identical results to the analysis of the true IPD.144
In this article we extend our method to creating pseudo IPD from available aggregate data for a continuous outcome, reported145
at two timepoints, at baseline and follow-up. Appropriate sufficient statistics for an analysis of covariance (ANCOVA) approach146
are, for each study separately, the means and standard deviations of the continuous outcome at baseline and follow-up in each147
group, together with the group correlation of the baseline and follow-up values. Our premise is to create pseudo IPD that148
have exactly these sample means, standard deviations, and correlations, so that the subsequent pseudo IPD meta-analysis will149
produce the same results as if the original IPD were available.150
The algorithm to construct for each of the studies and groups pseudo data with exactly the same mean, standard deviation151
and group correlation between baseline and follow-up measurement is as follows: let in a certain study arm, 푌̄퐵 , 푠푑퐵 and 푌̄퐹 ,152
푠푑퐹 be the observed means and SDs at baseline and follow-up, respectively and let 푟 be the correlation between baseline and153
follow-up measurement, and let 푛 be the sample size. Then for each group in each study separately, execute the following steps:154
1. Simulate two samples 푌 ∗푖1(푖 = 1, ..., 푛) and 푌
∗
푖2(푖 = 1, ..., 푛), from a certain distribution, for example a standard normal155
distribution.156
2. Standardise both samples to obtain 푌̄ ∗1 = 0 and 푌̄
∗
2 = 0, and 푠푑
∗
1 = 푠푑
∗
2 = 1 and calculate the correlation 푟
∗ between 푌 ∗푖1157
and 푌 ∗푖2.158
3. Regress 푌 ∗푖2 on 푌
∗
푖1 and keep the regression coefficients 훽̂ and the residuals 휖̂푖. Note that since 푠푑
∗
1 = 푠푑
∗
2 = 1, it follows159
that 훽̂푖 = 푟∗ and 휖̂푖 = 푌 ∗푖2 − 푟
∗푌 ∗푖1. Also note that the residuals are uncorrelated to 푌
∗
푖1 and have variance 1 − 푟
∗2.160
4. Generate 푌 ∗푖3 = 푌
∗
푖1푟 + 휖̂푖
√
1 − 푟2[
√
1 − 푟∗2]−1. Note that 푣푎푟(푌 ∗푖3) = 1 and its correlation with 푌
∗
푖1 is 푟.161
85. Generate the pseudo baseline as follows: 푌퐵푖 = 푌 ∗푖1푠푑퐵 + 푌̄퐵 .162
One can immediately verify that the pseudo baseline measurements have mean 푌̄퐵 and standard deviation 푠푑퐵 .163
6. Generate the pseudo follow-up outcome as follows: 푌퐹 푖 = 푌 ∗푖3푠푑퐹 + 푌̄퐹 .164
Similarly, the pseudo follow-up outcomes have mean 푌̄퐹 and standard deviation 푠푑퐹 and 푐표푟(푌퐵푖, 푌퐹 푖) = 푟.165
This algorithm can be easily carried out in standard statistical software. In the Supplementary material we show how this166
algorithm can be carried out in R31 and SAS32. The pseudo IPD can now be analysed using the LMM methods for IPD of167
Sections 3 and 4.168
In practice, the group correlations are rarely reported. However, the mean change from baseline, with the standard deviation
or standard error are more often provided. When the standard deviation at baseline, at follow-up and the change from baseline
푠푑퐶ℎ푎푛푔푒 are reported, the group correlation can be directly calculated as follows:
푟 =
푠푑2퐵 + 푠푑
2
퐹 − 푠푑
2
퐶ℎ푎푛푔푒푠푐표푟푒푠
2푠푑퐵푠푑퐹
(6)
For more details see the Cochrane Handbook33, Chapter 16. Alternatively, if the standard error of the difference between groups169
in mean change scores is provided and the pre/post correlations are assumed to be equal between the two groups; the correlation170
can be calculated as:171
푟 =
푠푑2퐵푇 ∕푛푇 + 푠푑
2
퐹푇 ∕푛푇 + 푠푑
2
퐵퐶∕푛퐶 + 푠푑
2
퐹퐶∕푛퐶 − 푠푒
2
푑푖푓퐶ℎ푎푛푔푒푠푐표푟푒푠
2푠푑퐵푇 푠푑퐹푇 ∕푛푇 + 2푠푑퐵퐶푠푑퐹퐶∕푛퐶
(7)
where 푇 and 퐶 are the indexes for treatment and control group, respectively21. When the group correlation cannot be derived172
from the available data, one could resort to imputation methods34,35,36.173
6 APPLICATION OF THE METHODS TO THE DATA174
We generated pseudo IPD baselines and outcomes for the aggregate hypertension data of Table 1, the aggregate hypertension175
dataset with artificial baseline imbalance and the AD of the obstructive sleep apnea example (given in the Supplementary176
material). Using these pseudo IPD we subsequently fitted the LMM models (1) to (4) discussed in Section 3; stratified study177
models and random study models, both with and without the interaction between treatment and baseline measurements. For178
the stratified models including the interaction term of baseline with the treatment effect, we assumed an unstructured variance-179
covariance matrix for the two random effects. For the random study models, we centered the groups when specifying the180
random effects, and assumed independent random effects due to memory issues. The parameters in the models were estimated181
using restricted maximum likelihood (REML37).182
We fitted all models using the LMM program of SAS, PROC MIXED because SAS has explicit options for modelling the183
within-study residual variances and allows for additional flexibility using different methods to calculate the degrees of freedom184
and hence confidence intervals of the treatment effect. We used two different approaches, the default method where the degrees185
of freedom are calculated using the “between within" method in SAS, as it was the method also used in our previous work and186
also the Satterthwaite approximation method38, following the recommendations of Legha et al.11, who performed an extensive187
simulation study comparing the models in Section 3 under different CI derivations options.188
In the Supplementary material we provide details on the SAS code and on how to fit the same models in R using nlme39. For189
comparison purposes with the results of Riley et al.21, we only show the CIs derived using the between-within method.190
6.1 Results of the hypertension example with baseline balance191
Results of the analyses using the pseudo IPD generated from the aggregate data on hypertension were compared with the two-192
stage IPD meta-analysis results of Riley et al.21, who (unlike us) had access to the original IPD. As mentioned a two-stage193
IPD meta-analysis is very similar to the stratified study model of Equation (1) assuming equal residual variances between the194
treatment and the control group per study, i.e study-specific variances: 휎2푖푘 = 휎
2
푖.. We also performed a two-stage ANCOVA195
using the pseudo IPD. For completeness we also present the results of an AD meta-analysis using the change scores.196
9The results for the baseline balanced example are shown in the top two rows of Table 2. Across all competing models, the197
treatment effect estimates were negative indicating that the hypertension treatment reduced systolic blood pressure values.198
The estimated treatment effect and corresponding standard error of the one-stage pseudo IPD ANCOVA analysis assuming199
study-specific residual variances, were identical to the results based on the analysis of the true IPD by Riley et al.21; -10.17200
(SE=0.93) vs -10.17 (SE=0.93). There are slight differences in the 95% CIs as they were derived by different methods; under201
the Satterthwaite correction method were slightly wider. In addiiton, a two-stage analysis on the pseudo IPD assuming study-202
specific residual variances yielded identical results to model (1) and the analysis of the true IPD21: a summary treatment effect203
of -10.17, SE= 0.93.204
We compared the AIC values40 of different within-study residual variance structures for the stratified study models and205
for the random study models. In both model blocks the lowest value was found for the assuming all within-study residual206
variances to be free (arm-specific and study specific; 243387.2), although AIC values were found to be very similar across the207
different within-study variance options, suggesting that one could potentially adopt a simpler model when opting for a more208
parsimonious model. The study stratified model assuming within-study variances to be study-specific had the second lowest209
AIC value (243411.9) in that model block and was adopted as the final model. This model showed a summary treatment effect210
of -10.17 [95% CI: (-12.27, -8.06)], indicating that on average antihypertension treatments have a positive effect on SBP levels,211
reducing them by 10.17 mmHg more compared with control/no treatment.212
The last column of Table 2 shows the results of the standard AD analysis following a change scores approach; a summary213
treatment effect -10.10 [95% CI: (-12.33, -7.87)], slightly lower than the ANCOVA estimate using one-stage or two-stage214
pseudo IPD.215
6.2 Results of the hypertension example with baseline imbalance216
For the aggregate data with baseline imbalance, the effect of the active hypertension treatments compared with control is more217
pronounced (bottom rows of Table 2). We adopt the stratified study model as the final model which produces a summary218
treatment effect of -14.55 [95% CI: (-18.31, -10.80)], identical to the ANCOVA result of the true IPD presented in Riley et al.21219
Using a two-stage analysis of the pseudo IPD assuming study-specific residual variances resulted also in a summary treatment220
effect of -14.55 [95% CI: (-18.30, -10.80)].221
The results of the pseudo IPD analysis were substantially different from the standard AD meta-analysis of change scores,222
because of the induced baseline imbalance.223
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TABLE 2 Meta-analysis results of summary treatment effect using the pseudo IPD approach compared with the true IPD and standard AD modelling approaches of Riley et
al.21
pseudo IPD meta-analysis true IPD meta-analysis AD meta-analysis
one-stage ANCOVA
ANCOVA model results as
described in Riley et al.21
Change scores
Dataset Model Results 휎2푖푘 휎
2
푖. 휎
2
.푘 휎
2 휎2푖.
Hypertension
(balanced)
Stratified study (Eq. 1)
훽̂1 -10.17 -10.17 -10.34 -10.34 -10.17 -10.10
SE 0.93 0.93 0.98 0.98 0.93 0.99
95% CI (-11.99, -8.34) (-12.27, -8.06) (-12.26, -8.43) (-12.26, -8.43) (-12.28, -8.05) (-12.33, -7.87)
휏21 7.12 7.11 8.17 8.17 7.15 6.56
Random study (Eq. 2)
훽̂1 -10.45 -10.46 10.56 -10.56
SE 0.99 0.99 1.01 1.01
95% CI (-12.39, -8.52) (-12.39, -8.53) (-12.53, -8.58) (-12.54, -8.59)
휏21 8.61 8.62 9.13 9.16
Hypertension
(imbalanced)
Stratified study (Eq. 1)
훽̂1 -14.57 -14.55 -14.58 -14.57 -14.55 -10.10
SE 1.65 1.66 1.64 1.65 1.66 0.99
95 % CI (-17.81, -11.33) (-18.31, -10.80) (-17.80, -11.36) (-17.78, -11.36) (-18.30, -10.80) (-12.33, -7.87)
휏21 25.28 25.47 25.30 25.19 25.43 6.56
Random study (Eq. 2)
훽̂1 -14.45 -14.46 -14.49 -14.48
SE 1.65 1.65 1.63 1.63
95% CI (-17.69, -11.20) (-17.67, -11.20) (-17.69, -11.29) (-17.68, -11.29)
휏21 25.34 25.23 25.10 24.99
CI: Confidence Interval, SE: standard error, 휎2푖푘 : study- and arm-specific variances, 휎
2
푖. : study-specific variances, 휎
2
.푘 : two variance parameters; one for control and one for treatment, 휎
2 : one overall variance
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6.3 Including the interaction between baseline and treatment effect224
To investigate potential treatment-by-baseline modification, we included the interaction term 훽3 between baseline and treatment225
effect in the pseudo IPD LMM models. We compared the pseudo IPD models (3) and (4) with the two-stage IPD meta-analysis226
of Riley et al.21 with interaction, and with a random-effects meta-regression of the final values on the mean baseline of the227
treatment group. The estimate obtained from the AD meta-regression is actually comparable to the 훽4 term, which quantifies tha228
across-trial interaction. In the results we focus on the within-trial interaction estimate 훽3 which reflects the treatment-by-baseline229
interaction.230
In the balanced example case, the derived pseudo IPD ANCOVA interaction term under the stratified study model assuming231
all within-study residual variances to be free was equal to -0.09 [95% CI: (-0.17, -0.01)], providing some evidence that the232
treatment effect is slightly higher for the more severe hypertensive patients at baseline with higher SBP baseline values (top233
row of Table 3). In addition, the result from model (3) assuming study-specific residual variances was found to be identical to234
the two-stage model fitted in Riley et al.21, -0.09 (SE:0.038). Using a two-stage analysis of the pseudo IPD assuming study-235
specific residual variances in SAS yielded a summary treatment-by-baseline interaction effect of -0.09 [95% CI: (-0.18, -0.00)].236
We also replicated the two-stage analysis in STATA using the DerSimonian-Laird method41 to combine the effects, where the237
results were found identical to the analysis in Riley et al21.238
The meta-regression results using the mean baseline value of the treatment group were higher compared with the pseudo IPD239
ANCOVA model (-0.16 vs -0.09).240
The estimates of the interaction effect in the imbalanced baseline dataset using the pseudo IPD were found to be very similar241
to the ones in the balanced case. However, the meta-regression estimate was in the opposite direction of the effect compared with242
the ANCOVA pseudo IPD results. The across-trial interaction as estimated from a standard AD meta-analysis can differ from243
the within-trial interaction, i.e. the difference in treatment effect of two patients in the same study differing one unit at baseline,244
as estimated from a true IPD or pseudo IPD meta-analysis. The assumption that they are the same is often not plausible due to245
the fact that across-trial interaction can suffer from confounding5. This phenomenon is called ecological or aggregation bias.246
Therefore the across-trials interaction should be carefully interpreted. Also note that the statistical power for the estimation of247
the within-trial interaction is usually much larger than for the across-trials interaction, as reflected by the standard errors (Table248
3).249
12
TABLE 3 Meta-analysis results of interaction of baseline with treament using the pseudo IPD approach compared with the true IPD and standard AD modelling
approaches of Riley et al.21
pseudo IPD meta-analysis true IPD meta-analysis AD meta-analysis
one-stage ANCOVA: including the
interaction
between baseline and treatment
ANCOVA model results as
described in Riley et al.21
Meta-regression
Dataset Model Results 휎2푖푘 휎
2
푖. 휎
2
.푘 휎
2 휎2푖. Using 푌̄퐵푇 푖
Hypertension
(balanced)
Stratified study (Eq. 3)
훽̂3 -0.09 -0.09 -0.10 -0.10 -0.09 -0.16
SE 0.04 0.04 0.04 0.04 0.03 0.05
95% CI (-0.17, -0.01) (-0.17, -0.01) (-0.18, -0.01) (-0.18, -0.01) (-0.16, -0.03) (-0.28, -0.04)
휏23 0.01 0.01 0.01 0.01 0.01 3.16
Random study (Eq. 4)
훽̂3 -0.09 -0.09 -0.10 -0.10
SE 0.04 0.04 0.04 0.04
95% CI (-0.17, -0.01) (-0.17, -0.01) (-0.18, -0.01) (-0.17, -0.02)
휏23 0.01 0.01 0.01 0.01
Hypertension
(imbalanced)
Stratified study (Eq. 3)
훽̂3 -0.09 -0.09 -0.10 -0.10 -0.09 0.20
SE 0.04 0.04 0.04 0.04 0.03 0.11
95% CI (-0.17, -0.01) (-0.17, -0.01) (-0.18, -0.01) (-0.18, -0.01) (-0.16, -0.03) (-0.76, 0.50)
휏23 0.01 0.01 0.01 0.01 0.01 47.85
Random study (Eq. 4)
훽̂3 -0.09 -0.09 -0.10 -0.11
SE 0.04 0.04 0.04 0.0
95% CI (-0.17, -0.01) (-0.17, -0.01) (-0.18, -0.01) (-0.19, -0.02)
휏23 0.010 0.011 0.012 0.012
CI: Confidence Interval, SE: standard error, 푌̄퐵푇 푖 : mean baseline SBP value of the treated group per trial, 휎
2
푖푘 : study- and arm-specific variances, 휎
2
푖. : study-specific variances, 휎
2
.푘 : two variance parameters; one for control and one for treatment, 휎
2 : one overall variance
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6.4 Results of the obstructive sleep apnea example250
In this second example, it was possible to calculate the group correlations (assumed to be equal between active and sham) using251
Equation (7); the derived correlations values varied slightly across studies [median: 0.498, IQR: 0.496-0.503]. We additionally252
performed sensitivity analyses by imputing three values of 푟 (0.5, 0.6 and 0.7), to simulate cases where deriving the correlations253
from available data would not be possible. The R package ggplot242 was used to visualise the results of the competing models.254
Figure 2 shows the results of the one-stage stratified study model assuming different options for the within-study residual255
variances. Results consistently showed that CPAP statistically significantly reduces AHI compared with the sham device (∼ 41256
events/hour). When 푟 was calculated from the summary data (blue line/circle estimate), the point estimates across competing257
models vary slightly between 41 and 42 less events per hour in favor of active CPAP. The lowest AIC value was found for the258
most flexible model assuming arm and study residual variances to be free (AIC = 2273). Overall, AIC values did not differ259
greatly across the models hence simpler structures can also be adopted, e.g., study-specific within-study residual variances260
model.261
The point estimates and 95% CIs were found to vary little across the imputed values of 푟, and the differences were not deemed262
to be clinically significant. The differences within the blocks of the more flexible modelling options (study- and arm- specific,263
and study-specific within-study residual variables) were more pronounced compared with the results of the more restricted264
models (group specific and one overall variance). Overall, the results based on the different imputed values within the same265
model block and across models did not seem to materially differ.266
For this example, no direct comparison is feasible with the true IPD, thus we present the results of the one- and two-267
stage pseudo IPD analysis (using the calculated 푟 value) and the original meta-analysis22, and compare them with each other268
(Table 4). The one-stage stratified study model and the two-stage ANCOVA model, which form a natural comparison with one269
anoother, produced identical results when rounded in two decimal places (rows 3-4, Table 4). The point estimate of the standard270
AD change score analysis was larger compared with the ANCOVA results of the pseudo IPD, which may be explained by the271
negative correlation of the change scores with the baseline scores and the worse baseline of the subjects randomised in the272
active group. Generating the pseudo IPD enabled us to explore the interaction of baseline values with the treatment effect which273
in this example was found to be statistically significant (last two rows of Table 4), suggesting that the treatment effect is higher274
for the patients randomised in the active CPAP arm who were found to suffer more at baseline compared to the control patients.275
FIGURE 2 Obstructive sleep apnea meta-analysis results: estimates of overall mean difference of active CPAP vs sham and
95% CI in AHI across different residual variance models and varying group correlation coefficients between baseline and
follow-up values.
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TABLE 4 Meta-analysis results of summary treatment effect and interaction effect using the pseudo IPD approach compared
with standard change score AD methods.
Approach Method Estimate Standard Error 95% CI
standard AD Difference in Change
scores as in Balk et al.22
-46.39 5.39 (-56.97, -35.81)
pseudo IPD
One-stage ANCOVA*†
Eq. (1)
-42.41 5.23 (-54.77, -30.05)
Two-stage ANCOVA
Eq. (5)
-42.41 5.23 (-54.77, -30.04)
One-stage ANCOVA
interaction effect
Eq. (3)
-0.40 0.07 (-0.54, -0.25)
Two-stage ANCOVA
interaction effect
-0.40 0.07 (-0.54, -0.25)
CI: Confidence Interval, †Assumed 푟퐶푃퐴푃 = 푟푠ℎ푎푚 = 0.5, *A study-stratified model with study specific variances was used, 푌̄퐵푇 푖 : mean baseline AHI values of the treated group per trial
7 DISCUSSION276
We have shown how aggregate data from comparative studies of continuous outcomes measured at baseline and follow-up can277
be analysed by generating pseudo IPD. These pseudo IPD enable us to use the complete palette of techniques available for IPD278
meta analyses. In particular, we are able to (1) perform an ANCOVA, where we can adjust for baseline imbalances between279
treatment and control groups and to (2) explore interactions between baseline values and treatment effects. Different modelling280
approaches of increasing complexity can be applied by using the linear mixed model (LMM) framework. Since the LMM281
analyses are likelihood-based, one-stage and two-stage results derived using the pseudo IPD baseline and follow-up outcomes282
are identical to the ones of the original IPD. The proposed methods can be applied in any standard statistical software therefore283
eliminating the need for training on a special purpose meta-analytic software.284
In this article we have described modelling situations of comparing two treatment groups using the follow-up and baselines285
values. However, the LMM is a broad framework which offers rather staightfoward extensions of this work; the algorithm is286
directly generalisable to repeated measures meta-analysis and to multiple-treatments meta-analysis. Extension of the method for287
meta-analysis of cross-over trials is also applicable with some modifications albeit beyond the scope of this work. In addition,288
incorporation of non-linear covariates or non-linear interactions of treatment with continuous covariates could be a topic of289
future research as in this work we included the baseline (our covariate of interest) as a linear term in the ANCOVA model.290
Our algorithm could be extended to incorporate other covariates than only the baseline if the required summary statistics are291
available, in this case the variance-covariance matrix per group. These summaries are practically never reported however it is292
much easier to request them from the authors compared to the true IPD, as no privacy issues are involved. Bonofiglio and authors293
recently proposed a similar approach under distributed computing setting framework using only IPD summaries to recreate the294
marginal distributions of the original IPD considering eight baseline predictors in a multivariable logistic regression model43.295
The proposed approach successfully addresses the problem of IPD disclosure which is seldom possible due to various reasons296
with respect to data privacy and data security. In the case of continuous outcomes measured at baseline and follow-up often297
the sufficient aggregate data may be only partially available; for example often only means and standard deviations at baseline298
and mean change from baseline scores with the respective standard deviation or standard error are reported. Less frequently299
the mean and the standard deviation values at follow-up are provided. In that case, we could resort to algebraic calculations300
or imputation methods36,34. In principle, the minimally required set of aggregate data is the means and standard deviations301
at baseline and follow-up and also the standard deviation of the change from baseline. If these three standard deviations are302
provided, the correlation coefficient of baseline and follow-up can be calculated33. If one of these standard deviations are303
missing, they can potentially be algebraically extracted by other commonly reported summary statistics, e.g., confidence interval304
of mean difference, standard error of mean difference, paired t-test or a p-value from a paired t-test44,45,46. In cases where305
the post-baseline standard deviation is missing, it is common practice to assume it equal to the standard deviation at baseline306
and thus enable the calculation of the within-group correlation. Another commonly used approach is to impute the missing307
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SDs at post-baseline from other similar studies, with respect to study and patient characteristics, included in the meta-analysis.308
Recently, Weir and colleagues36 proposed fifteen methods for addressing missing standard deviations (and by extension group309
correlations) in continuous data meta-analysis, building on the empirical review of Wiebe and colleagues in 200634. Interested310
readers are referred to these reviews as a lengthy description of available methods for calculating or imputing the missing311
summary data is beyond the scope of this work. We also encourage contacting the authors of the original studies to provide the312
aggregate data also at follow-up, when confidentiality issues prohibit the direct provision of IPD.313
We compared our pseudo IPD approach to standard meta-analytic approaches for aggregate data: random effects meta-314
analysis using change scores and meta-regression of the final scores on the baseline values of the treatment group to compare315
their performance with the pseudo IPD models. In case of imbalanced baseline values, the AD methods based on change scores316
tend to provide biased treatment and interaction effect estimates compared with the pseudo IPD ANCOVA methods.317
Another advantage of the pseudo IPD approach is that it allows us to make more realistic and flexible assumptions regarding318
the within-study residual variances. In the absence of computational or estimations issues, we propose to use a realistic structure319
of the within-study residual variance. This flexibility is not possible in the standard AD analysis. Moreover, the standard AD320
assumes the standard errors of the treatment effects to be fixed and known, while using pseudo IPD ANCOVA methods may321
account for the fact that these are estimated.322
When the appropriate AD are available (i.e., two means, standard deviations and correlation per group), we strongly323
recommend our proposed methodology to construct the pseudo IPD and perform an ANCOVA, if needed including the324
treatment-by-baseline interaction term. The advantage of our method is highlighted particularly in the case of baseline imbal-325
ance and in the case of treatment-baseline interaction, as the standard AD methods for interaction are known to suffer from low326
power and the potential of ecological-bias.327
HIGHLIGHTS328
What is already known?329
The meta-analysis of IPD has been advocated as the "gold-standard" of evidence synthesis for many years. The generally330
preferred method to analyse IPD with continuous measurements at baseline and follow-up is linear mixed effects ANCOVA331
model. However access to IPD is often impossible. Researchers thus resort in an AD meta-analysis where in case of baseline332
imbalances, the treatment effects, derived by other methods than ANCOVA, may be biased.333
What is new?334
We provide an algorithm which makes use of summary reported AD of continuous measurements at baseline and follow up for335
to construct pseudo IPD. These pseudo IPD can be analysed in the same way as the original IPD using ANCOVA, producing336
identical results. Therefore we can adjust for baseline imbalances between treatment and control groups and explore interactions337
between baseline values and treatment effects. In the example dataset where the true IPD have been synthesized, the results of338
our analysis were identical to the true original IPD results.339
What is the potential impact for RSM readers outside the author’s field?340
To enable reproducibility and dissemination of the method, we have provided implementation code of the algorithm both in R341
and SAS. Meta-analysis is a statistical technique undertaken by researchers from various fields and thus being able to use the342
provided code in easily accessible free and commercial software can only improve the quality of their work.343
DATA AVAILABILITY STATEMENT344
The data that supports the findings of this study are available in the supplementary material of this article.345
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TABLE S1 Aggregate data of the 8 trials included in the meta-analysis of Balk et al.22
Number of subjects AHI index at baseline AHI index at follow-up Reported
correlation
Calculated correlation
using Eq. (7)
Treatment Control Treatment Control
Equal between treatment
and control groups
ID Trial name Treatment Control Mean (SD) Mean (SD) Mean (SD) Mean (SD)
1 Egea 2008 27 29 43.7 (22.9) 35.3 (16.7) 10.8 (11.4) 28.0 (24.8) - 0.4979
2 Haensel 2007 25 25 65.9 (28.6) 57.5 (32.1) 3.5 (3.4) 53.4 (32.9) - 0.4981
3 Loredo 1999 23 18 56.4 (24.1) 44.2 (25.3) 3.3 (3.8) 28.3 (22.7) - 0.4442
4 Mills 2006 17 16 65.0 (34.0) 61.2 (41.0) 2.6 (2.4) 57.3 (41.0) - 0.4969
5 Loredo 2006 22 19 65.9 (28.6) 57.5 (32.1) 3.0 (4.7) 52.5 (37.5) - 0.5704
6 Norman 2006 18 15 66.1 (29.1) 53.9 (29.8) 3.4 (3.0) 50.1 (32.1) - 0.4967
7 Becker 2003 16 16 62.5 (17.8) 65.0 (26.7) 3.4 (3.1) 33.4 (29.2) - 0.5025
8 Spicuzza 2006 15 10 55.3 (11.9) 59.2 (17.3) 2.1 (0.3) 57.0 (8.6) - 0.5052
AHI: Apnea-hypopnea index, SD: standard deviation
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